Purpose. This study evaluated the treatment outcomes of supraciliary microstent implantation (CyPass® Micro‑Stent, Transcend Medical, USA) in patients with open‑angle glaucoma undergoing cataract surgery. Material. Prospective case series. Methods. Twenty patients (mean age: 76.5 ±7.1 years) were evaluated for 36 months after supraciliary microstent implantation combined with cataract surgery. Evaluated outcomes included IOP, best‑corrected visual acuity (BCVA), number of required IOP‑lowering medications, and adverse events. Results: Baseline mean IOP (16.1 ±3.3 mm Hg) remained well‑controlled at 36‑months post‑surgery (15.8 ±3.4 mm Hg; p =0.070). Baseline BCVA (mean 20/40 Snellen, range 20/25–20/200) was improved after surgery, and the effect was maintained through postoperative 36‑months (mean 20/25 Snellen, range 20/20–20/80). All subjects used IOP‑drugs at baseline (40% required ≥3 medications), whereas 80% remained medication‑free at postoperative 36‑months. One stent obstruction resulted in elevated IOP and device explantation. Another subject experienced persistent corneal edema. Adverse events included transiently elevated IOP (20% of eyes) and hypotony (20%). Conclusion. Supraciliary microstenting combined with cataract surgery in open‑angle glaucoma results in minimal complications and significantly reduces necessary IOP‑lowering medications through postoperative 36‑months.